How does life change after your name is called at NHL Draft: A breakdown
The National Hockey League entry draft always is an educated gamble for franchises looking to expand their prospect pools, as well as an important career checkpoint for players who intend to go pro.
Article content
It also has been seen as the league's well-attended annual conference, but this draft, to be held Friday and Saturday at the Peacock Theatre in Los Angeles, will be different.
Article content
Instead of teams sending the usual complement of about 20 scouts, coaches and support staff, some organizations will be represented by as few as two people; one each from their communications and player development departments.
Article content
The remainder of each staff will monitor and participate in the draft from their own markets, following in the footsteps of the National Football League, National Basketball Association and Major League Baseball.
Article content
The NHL was forced into this decentralized format by the COVID-19 pandemic. Fresh off that experience, team executives voted 26-6 to return to a decentralized event in 2025, citing cost savings and augmented privacy surrounding their hockey operations.
Article content
Article content
However, the excitement generated by the glitzy 2024 centralized event, held in the Sphere in Las Vegas, apparently has given some executives second thoughts and the 2025 draft may be an outlier, rather than a trendsetter.
Article content
'Prospects will be seated in the Peacock Theatre similar to the way they were situated last year in the Sphere,' NHL senior manager of event communications Dave Keon Jr. said in an email. 'Once they are selected, they will walk to the stage and meet the commissioner as in the past.
Article content
Article content
'After that, they will meet the team that selected them virtually as well as do rights-holder interviews backstage. Once the prospect is finished with the rights-holders, he will head to the media avail with media on site. The PR staff from the team may also make the prospect available to media not in attendance via Zoom.'
Article content
Back in the day, public relations director Bill Tuele was the first point of contact for Edmonton Oilers draft picks.
Article content
'We had 10 or 12 jerseys under the table and a box full of name bars with sticky backs, most of whom would never be drafted, at least not by us, but you had to have them in case strange things happened,' Tuele said. '(Chief scout Barry Fraser or GM Glen Sather) would tell me who was going to be drafted and I would ask him the obvious question: 'is he here?' Barry would say 'yeah he's here,' and there would be this surreptitious pointing to where he was so I could pre-identify where I had to go to get him.
Article content
'Once (commissioner Gary Bettman) or whomever announced the pick, the kid would go through the normal family stuff and walk down to the floor. I would introduce myself, say congratulations, take his jacket, and we would walk toward the podium on the stage, at which point I would give either Barry or Slats the sweater. The player puts on the sweater and hat, poses for the NHL (photographer) and our guy, and then the photogs would have to scurry, because instead of walking off to do a brief interview with (TSN's) James Duthie or whoever, they didn't have that in my day.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
Can DICK'S Sporting's Digital Push Power the Next Leg of Growth?
DICK'S Sporting Goods, Inc. 's DKS digital strategy has been a key growth driver. The company is making bold strides in digital transformation, firmly positioning itself as a leading omnichannel player in the sports industry. DKS' GameChanger platform and the Dick's Media Network are significant pillars fueling its long-term digital revenue streams. While GameChanger serves as a high-margin growth engine, Dick's Media Network is a retail media platform that capitalizes on the growing scorecard loyalty program and customer data ecosystem. Through GameChanger, the company engages with athletes beyond the traditional shopping experience, further reinforcing its dominance in sports. In first-quarter fiscal 2025, DKS recorded more than 6.5 million unique active users, with an average of approximately 2.2 million daily active users, reflecting 28% growth. DKS witnessed robust e-commerce results in first-quarter fiscal 2025, outpacing its overall growth. It achieved the largest Diamond Sports launches to date, complemented by an elevated, diversified assortment positioning DKS as the go-to destination for the new product. DICK'S Sporting's in-app capabilities have played a vital role in driving the success of its product launches across categories. The company is rapidly scaling its multi-billion dollar e-commerce business by fortifying its online presence and capturing market share from both online only and omnichannel retailers. DKS is making significant investments in technology to offer a seamless omnichannel experience to athletes and drive greater engagement across its digital platforms, including Its access to top-tier products from national and emerging brands, paired with premium in-store and digital experiences, will continue to bolster demand and solid sell-through on launches. DKS' Position Among Competitors As DICK's strengthens its position through a focused omnichannel strategy, it continues to face intense competition from retail heavyweights such as Inc. AMZN, NIKE, Inc. NKE and lululemon athletica inc. LULU. In the whirlwind of technological advancements, Amazon has emerged as a leading example of shaping digital infrastructure to build customer satisfaction. The company strategically leverages its AI-based technologies in sync with its broader digital-transformation actions. Amazon's renowned subscription service, Prime, started as a free two-day shipping and has evolved into a comprehensive platform offering streaming media, exclusive deals and other member benefits. Amazon's digital marketing strategy, including quick delivery options and adaptability to meet customer evolving needs, is a key catalyst of its revenue driver. As a global sports leader, NIKE continues to make substantial investments in its digital platform in a bid to drive customer engagements and higher revenues. NIKE transitioned to a push marketing approach at the start of fiscal 2025, and its digital platforms reflect an approximately equal balance between full-price and promotional sales. NIKE prioritizes a direct-to-consumer approach, with platforms like the Nike App, SNKRS App and other social media channels to boost direct consumer engagements and offer top personalized experiences. lululemon prioritizes e-commerce as a vital growth pillar, boosting digital investments to capture the increasing online demand. lululemon's initiatives aim at site development, enhanced omnichannel functionality and expanded fulfillment capabilities. The company is scaling services such as curbside pickup, same-day delivery, and buy online, pick up in-store while upgrading its mobile app to support these offerings. Store associates are also being trained to streamline digital-to-physical transactions, reinforcing lululemon's commitment to a seamless, high-touch customer experience across all channels. Digital revenues rose 6% year over year in first-quarter fiscal 2025. DKS' Price Performance, Valuation and Estimates Shares of DICK'S Sporting have lost 13.3% year to date compared with the industry 's decline of 5.1%. Image Source: Zacks Investment Research From a valuation standpoint, DKS trades at a forward price-to-earnings ratio of 13.24X compared to the industry's average of 16.75X. The Zacks Consensus Estimate for DKS' fiscal 2025 and fiscal 2026 earnings implies year-over-year growth of 2.4% and 7.1%, respectively. The company's EPS estimate for fiscal 2025 has been on the rise while that of fiscal 2026 has moved down in the past 30 days. DICK'S Sporting stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report DICK'S Sporting Goods, Inc. (DKS): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report
Globe and Mail
19 minutes ago
- Globe and Mail
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity ('LOE') of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and are expected to support top-line growth in the next few years. AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth. AbbVie, however, faces its share of headwinds, like Humira biosimilar erosion, increasing competitive pressure on Imbruvica and slowing sales of its aesthetics franchise. Let's understand the company's strengths and weaknesses to better analyze how to play ABBV stock amid the market value growth. ABBV's Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the LOE and biosimilar erosion. However, with approvals for many new indications, sales of Skyrizi and Rinvoq have successfully replaced Humira, which once generated more than 50% of its total revenues. Skyrizi and Rinvoq generated combined sales of $5.1 billion in the first quarter of 2025, reflecting growth of more than 65%. The drugs are seeing strong performance across all approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions — ulcerative colitis (UC) and Crohn's disease (CD). Importantly, Skyrizi and Rinvoq have demonstrated compelling head-to-head data against several novel therapies in clinical studies, which have given them a competitive advantage. AbbVie expects combined sales of Skyrizi and Rinvoq to be around $24.7 billion in 2025 and more than $31 billion by 2027. Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' growth. ABBV Boasts an Attractive Pipeline AbbVie has several early/mid-stage pipeline candidates with blockbuster potential. The company expects several regulatory submissions, approvals and key data readouts in the next 12 months. ABBV has an exciting and diverse pipeline of promising new therapies in blood cancers and solid tumors, like ABBV-383, a BCMA CD3 bispecific (relapsed/refractory multiple myeloma) and Temab-A (metastatic colorectal cancer). Emrelis (previously Teliso-V), a promising antibody drug conjugate or ADC, was approved in the United States for previously treated non-squamous non-small cell lung cancer with high c-Met expression in May 2025. In other areas, some key pipeline drugs are lutikizumab for immunology indications and tavapadon for early Parkinson's disease. AbbVie expects to file a new drug application for tavapadon this year. AbbVie on an Acquisition Spree The company has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. It has signed several M&A deals in the immunology space, its core area, while also inking some early-stage deals in oncology and neuroscience. It has signed more than 20 early-stage deals since the beginning of 2024, including promising technologies and innovative mechanisms that can elevate the standard of care in immunology, oncology and neuroscience. In early 2025, AbbVie bought rights to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity, from Denmark's Gubra. The deal marked AbbVie's entry into the obesity space, dominated by Eli Lilly LLY and Novo Nordisk NVO. AbbVie plans to invest further in obesity. ABBV's Slowing Aesthetics Sales & Humira Erosion Sales of AbbVie's blockbuster drug Humira are declining due to biosimilar erosion. Humira volume is rapidly eroding compared to other novel mechanisms (including Skyrizi and Rinvoq). Humira sales declined by almost 50% in the first quarter of 2025, primarily due to faster erosion of its share as a result of biosimilar competition, as well as further molecule compression in the United States. AbbVie is witnessing declining sales of Juvederm fillers in the United States and China due to challenging market conditions. The slowing growth of the U.S. facial injectables market and persistent economic headwinds, which are affecting consumer spending in China, are hurting AbbVie's aesthetics portfolio sales, which declined 10.2% in the first quarter of 2025. ABBV Stock Price, Valuation and Estimate Revision AbbVie's stock has gained 7.1% so far this year against a decrease of 0.7% for the industry. The stock has also outperformed the industry and the S&P 500 index, as seen in the chart below. ABBV Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, AbbVie is not very cheap. Going by the price/earnings ratio, the company's shares currently trade at 14.21 forward earnings, just slightly lower than 14.87 for the industry. The stock is cheaper than some other large drugmakers like Eli Lilly and Novo Nordisk, but is priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.44. ABBV Stock Valuation The Zacks Consensus Estimate for 2025 earnings has risen from $12.21 per share to $12.28, while that for 2026 has increased from $14.03 to $14.06 per share over the past 30 days. ABBV Estimate Movement Stay Invested in ABBV Stock Though AbbVie faces its share of near-term headwinds, the company has faced its biggest challenge — Humira's patent cliff — quite well and looks well-positioned for continued strong growth in the years ahead. AbbVie expects to return to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. AbbVie's ex-Humira drugs rose delivered robust sales growth of more than 21% (on a reported basis) in the first quarter of 2025. Boosted by its new product launches, AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE event for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. Rising estimates for AbbVie, its solid pipeline and the prospect of growth in 2025 sales and profits are good enough reasons to stay invested in this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
Globe and Mail
19 minutes ago
- Globe and Mail
Kinder Morgan Surpasses Industry Gains: What Investors Should Know
Shares of Kinder Morgan, Inc. KMI have gained 45.4% in the past year, outperforming the oil-energy sector's gain of 26.5% and the S&P 500's gain of 11.3%. The company has a market capitalization of $63 billion. The company also outperformed its peers, such as MPLX LP MPLX and Enbridge, Inc. ENB, which have gained 20.3% and 26.7%, respectively, over the same time frame. Positive Outlook on KMI's Growth Trajectory The Zacks Consensus Estimate for KMI's 2025 earnings is pegged at $1.26, implying a year-over-year improvement of 9.6%. The consensus estimate for KMI's 2025 revenues is pegged at $16.5 billion, implying a year-over-year improvement of 9.4%. Kinder Morgan's earnings grew 4.9% in the last five years, better than the industry average of 4.4%. Long-term earnings growth is expected to be 7.2%, better than the industry average of 6.7%. Average Target Price for KMI Suggests Upside Based on short-term price targets offered by 15 analysts, the Zacks average price target is $31.40 per share. The average suggests a 10.9% upside from the last closing price. Factors to Consider Kinder Morgan presents a compelling investment case grounded in stable cash flows, strategic natural gas infrastructure, and forward-looking capital deployment. At the core of its financial model is a highly predictable earnings stream, approximately 95% of its 2025 budgeted cash flow comes from take-or-pay, fee-based, or hedged contracts. This structure protects the company against commodity price volatility and volume fluctuations. The take-or-pay model, which accounts for 64% of the total, ensures payment from counterparties regardless of actual throughput, while the fee-based and hedged arrangements further stabilize revenue. This setup supports Kinder Morgan's robust 2025 financial guidance of $5.2 billion in distributable cash flow and $1.27 billion in adjusted earnings per share, indicating 10% and 4% year-over-year growth in EPS and EBITDA, respectively. Strategically, Kinder Morgan is deeply embedded in the U.S. natural gas market, which is projected to experience significant growth through the end of the decade. Demand is expected to rise by 20-28 billion cubic feet per day (bcfd) by 2030, largely driven by LNG exports, power generation needs (especially as coal retires), and increased industrial usage. The company is positioned to benefit directly from this surge, with long-term contracts already in place. Kinder Morgan's footprint is particularly strong in Texas and Louisiana, regions anticipated to account for over 95% of total U.S. demand growth in this timeframe. The company's dominant position in natural gas transportation is a key differentiator. Kinder Morgan owns and operates 66,000 miles of natural gas pipelines, which move around 40% of U.S. production. It also controls over 700 billion cubic feet of working storage, accounting for 15% of national capacity. The scale of this infrastructure not only supports efficient delivery to high-demand markets, including power plants and export terminals, but also provides operational leverage and competitive moat advantages. Kinder Morgan is also actively participating in the broader energy transition. Through its Energy Transition Ventures group, it is building a portfolio of renewable natural gas (RNG) assets with 6.4 bcf of annual production capacity and is evaluating carbon capture and storage (CCS) opportunities. These investments leverage its existing pipeline expertise and position it to serve emerging low-carbon markets. Furthermore, approximately $8 billion of its current capital project backlog includes components related to lower-carbon initiatives such as RNG and CCS. Lastly, the company has demonstrated a strong commitment to sustainability and governance. It received an MSCI ESG rating upgrade to AAA in 2024 and ranks among the top performers in its industry according to Sustainalytics, FTSE, and Refinitiv. Operationally, it has achieved an ~8% reduction in methane emissions since 2021 and surveys 100% of its natural gas compressor stations every quarter. These practices, alongside improved board diversity and employee safety metrics, reinforce Kinder Morgan's positioning as a responsible infrastructure operator. Risks One key risk factor for Kinder Morgan is its partial exposure to commodity price volatility, particularly within its Enhanced Oil Recovery (EOR) operations and certain natural gas Gathering & Processing (G&P) projects. While 95% of KMI's cash flows are secured through take-or-pay, fee-based, or hedged structures, around 5% remain unhedged, making them sensitive to market fluctuations. The EOR segment, in particular, generates revenue based on oil prices and production volumes, which can lead to earnings variability during periods of commodity price weakness. Hence, it is better to stay cautious about this Zacks Rank #3 (Hold) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Enbridge Inc (ENB): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report
